You are here: Industry Insights > ALS

News List

Sartorius Acquires Stake in ALS Expanding Bioanalytics Portfolio contractpharma
December 17, 2021
Gains solutions for the automated analysis, selection and isolation of cells.
Sartorius Acquires a Majority Stake in ALS Automated Lab Solutions AmericanPharmaceuticalReview
December 17, 2021
The life science group Sartorius is expanding its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions GmbH.
Lilly and Verge Genomics partner to use AI for drug development pharmaceutical-technology
July 12, 2021
Eli Lilly has entered a three-year partnership with biotech company Verge Genomics to research and create new drugs for the treatment of amyotrophic lateral sclerosis (ALS), a motor neuron disease.
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China prnasia
July 05, 2021
Sperogenix (Shanghai) MedTech Co., Ltd., a subsidiary of Sperogenix Therapeutics (platform company for development and commercialization of rare diseases medications in China), has entered into an exclusive licensing agreement with Abbisko ...
Local pharma to begin phase 2 clinical trial for Lou Gehrig’s disease therapy firstwordpharma
June 18, 2021
South Korea's drug regulator has granted approval for a Phase IIa trial of Helixmith's investigational gene therapy Engensis for treating amyotrophic lateral sclerosis (ALS), reported The Korea Herald.
CRISPR, Capsida team up on gene-edited therapies for ALS, Friedreich's ataxia firstwordpharma
June 16, 2021
CRISPR Therapeutics has inked a partnership with newly launched Capsida Biotherapeutics to develop and commercialise in vivo gene-editing therapies delivered with engineered adeno-associated virus (AAV) vectors for the treatment of familial amyotrophic
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis americanpharmaceuticalreview
June 09, 2021
Spinogenix, Inc. announced it has been granted Orphan Drug Designation (ODD) for SPG302 in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) by the U.S. FDA.
Scientists discover a new genetic form of ALS in children firstwordpharma
June 01, 2021
NIH- and USU- led study links ALS to a fat manufacturing gene and maps out a genetic therapy
Aeterna Zentaris Starts Preclinical Development of Macimorelin as a Potential Treatment for ALS americanpharmaceuticalreview
May 18, 2021
Aeterna Zentaris Inc. has announced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).
Amylyx Pharma plans to file ALS therapy with the EMA this year pharmatimes
April 16, 2021
Amylyx Pharmaceuticals has announced its intention to submit a marketing authorisation application for its investigational amyotrophic lateral sclerosis (ALS) therapy AMX0035 to the European Medicines Agency (EMA) by the end of 2021.

Previous page 1 2 3 4 5 6 7 8 Next page